Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Repaglinide

FDA-approved product (tablet, oral), marketed as Prandin, Repaglinide.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Repaglinide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Diabetes mellitus
  • Type 2 diabetes mellitus

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other blood glucose lowering drugs, excl. insulins
FDA pharmacologic class
Glinide FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA37.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli34.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae27.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis55.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Repaglinide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Repaglinide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Drug-drug Interaction Study to Evaluate the Effects of Pelabresib on the Pharmacokinetics of Repaglinide, Midazolam, and Combined Oral Contraceptive in Patients With Advanced Malignancies

    NCT07340190 · start 2026-06-12

    Registered record
    Registry ID
    NCT07340190
    Conditions
    Advanced Malignancies
    Interventions
    pelabresib; repaglinide; midazolam; drospirenone; ethinyl estradiol
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2026-06-12
    Completion
    2028-04-07
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdvanced Malignancies
    Interventionpelabresib; repaglinide; midazolam; drospirenone +1 more
    PhasePhase 1
    Registry statusRecruiting

  • Pralsetinib DDI Study in Patients With Advanced or Metastatic Solid Tumors

    NCT07704658 · start 2026-03-04

    Registered record
    Registry ID
    NCT07704658
    Conditions
    NSCLC (Non-small Cell Lung Cancer); Thyroid Cancer; Solid Tumor Malignancies; Advanced Malignancies
    Interventions
    Pralsetinib; CYP3A4, CYP2C8, and CYP2C9 substrates, and hormonal contraceptive
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2026-03-04
    Completion
    2027-08-30
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNSCLC (Non-small Cell Lung Cancer); Thyroid Cancer; Solid Tumor Malignancies; Advanced Malignancies
    InterventionPralsetinib; CYP3A4, CYP2C8, and CYP2C9 substrates, and hormonal contraceptive
    PhasePhase 4
    Registry statusRecruiting

  • A Study to Investigate the Effects of Multiple Doses of Rezatapopt on the Pharmacokinetics of Metformin, Rosuvastatin, Repaglinide, and Midazolam in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation.

    NCT07372625 · start 2026-02-04

    Registered record
    Registry ID
    NCT07372625
    Conditions
    TP53 Y220C Mutation; Advanced Solid Tumors
    Interventions
    metformin hydrochloride 500 mg tablet; rosuvastatin 10 mg tablet; repaglinide 0.5 mg tablet; midazolam hydrochloride syrup; rezatapopt
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2026-02-04
    Completion
    2028-01
    Enrolment
    14

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionTP53 Y220C Mutation; Advanced Solid Tumors
    Interventionmetformin hydrochloride 500 mg tablet; rosuvastatin 10 mg tablet; repaglinide 0.5 mg tablet; midazolam hydrochloride syrup +1 more
    PhasePhase 1
    Registry statusRecruiting

  • Drug-drug Interaction Study of Vorasidenib With Bupropion, Repaglinide, Flurbiprofen, Omeprazole, Midazolam, and Rosuvastatin in Healthy Adult Participants

    NCT07235748 · start 2025-10-07

    Registered record
    Registry ID
    NCT07235748
    Conditions
    Healthy Adult Participants
    Interventions
    Vorasidenib; Bupropion; Flurbiprofen; Omeprazole; Midazolam; Repaglinide; Rosuvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2025-10-07
    Completion
    2025-12-23
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Adult Participants
    InterventionVorasidenib; Bupropion; Flurbiprofen; Omeprazole +3 more
    PhasePhase 1
    Registry statusCompleted

  • A Study to Investigate the Effect of AZD5004 on Rosuvastatin, Atorvastatin, Simvastatin, Repaglinide and the Effect of Erythromycin on AZD5004 in Healthy Participants

    NCT06948747 · start 2025-05-06

    Registered record
    Registry ID
    NCT06948747
    Conditions
    Healthy Participants
    Interventions
    AZD5004; Rosuvastatin; Erythromycin; Atorvastatin; Simvastatin; Repaglinide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2025-05-06
    Completion
    2025-10-03
    Enrolment
    49

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Participants
    InterventionAZD5004; Rosuvastatin; Erythromycin; Atorvastatin +2 more
    PhasePhase 1
    Registry statusCompleted

  • KF2022#4-trial: Effects of a Beta Blocker and NSAID on CYP Mediated Drug Metabolism

    NCT06566794 · start 2024-08-22

    Registered record
    Registry ID
    NCT06566794
    Conditions
    Drug Interaction
    Interventions
    Caffeine Tablet; Bupropion Hydrochloride Capsels; Repaglinide Capsels; Flurbiprofen Capsels; Omeprazole 10 MG; Dextromethorphan Oral Solution; Midazolam oral solution; Simvastatin tablets; Placebo; Carvedilol; Diclofenac
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2024-08-22
    Completion
    2025-01-10
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug Interaction
    InterventionCaffeine Tablet; Bupropion Hydrochloride Capsels; Repaglinide Capsels; Flurbiprofen Capsels +7 more
    PhaseNot applicable
    Registry statusCompleted

  • A Study in Healthy Men to Test Whether Zongertinib Affects How 3 Other Medicines (Midazolam, Omeprazole, and Repaglinide) Are Taken up and Processed by the Body

    NCT06494761 · start 2024-07-30

    Registered record
    Registry ID
    NCT06494761
    Conditions
    Healthy
    Interventions
    zongertinib; midazolam; omeprazole; repaglinide
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2024-07-30
    Completion
    2024-10-16
    Enrolment
    16

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Interventionzongertinib; midazolam; omeprazole; repaglinide
    PhasePhase 1
    Registry statusCompleted

  • A Study in Healthy Men and Women to Test Whether BI 1569912 Influences the Amount of Repaglinide, Midazolam and Bupropion in the Blood

    NCT06367153 · start 2024-05-15

    Registered record
    Registry ID
    NCT06367153
    Conditions
    Healthy
    Interventions
    BI 1569912; Repaglinide; Midazolam; Bupropion
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2024-05-15
    Completion
    2024-08-20
    Enrolment
    18

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionBI 1569912; Repaglinide; Midazolam; Bupropion
    PhasePhase 1
    Registry statusCompleted

  • A Study of the Interaction of Other Drugs With TAK-279 in Healthy Adults

    NCT06290050 · start 2024-03-29

    Registered record
    Registry ID
    NCT06290050
    Conditions
    Healthy Volunteers
    Interventions
    Midazolam; Repaglinide; TAK-279
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2024-03-29
    Completion
    2024-05-16
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionMidazolam; Repaglinide; TAK-279
    PhasePhase 1
    Registry statusCompleted

  • PK Effects of SHR4640 on Repaglinide and Midazolam, and the Impact of SHR4640 on QT Interval

    NCT06196580 · start 2024-01-04

    Registered record
    Registry ID
    NCT06196580
    Conditions
    Gout and Hyperuricemia
    Interventions
    repaglinide; midazolam; SHR4640; repaglinide; midazolam; SHR4640; SHR4640 placebo; repaglinide; midazolam; SHR4640 placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2024-01-04
    Completion
    2024-02-16
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGout and Hyperuricemia
    Interventionrepaglinide; midazolam; SHR4640; repaglinide +6 more
    PhasePhase 1
    Registry statusCompleted

  • Voxelotor CYP and Transporter Cocktail Interaction Study

    NCT05981365 · start 2023-04-17

    Registered record
    Registry ID
    NCT05981365
    Conditions
    Sickle Cell Disease
    Interventions
    Voxelotor; Bupropion; Repaglinide; Flurbiprofen; Omeprazole; Midazolam; Metformin; Furosemide; Rosuvastatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2023-04-17
    Completion
    2023-10-04
    Enrolment
    44

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSickle Cell Disease
    InterventionVoxelotor; Bupropion; Repaglinide; Flurbiprofen +5 more
    PhasePhase 1
    Registry statusCompleted

  • A Pharmacokinetic Study to Evaluate the Drug Interaction Between SHR0302 and CYP Substrates in Healthy Volunteers

    NCT05392127 · start 2022-07-15

    Registered record
    Registry ID
    NCT05392127
    Conditions
    Rheumatoid Arthritis
    Interventions
    SHR0302 Tablets; Midazolam Maleate Tablets; Warfarin Sodium Tablets; Omeprazole Enteric Capsules; Vitamin K1 Tablets; Repaglinide Tablets
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-07-15
    Completion
    2022-08-18
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRheumatoid Arthritis
    InterventionSHR0302 Tablets; Midazolam Maleate Tablets; Warfarin Sodium Tablets; Omeprazole Enteric Capsules +2 more
    PhasePhase 1
    Registry statusCompleted

  • A Study of Imlunestrant (LY3484356) in Female Healthy Participants

    NCT05444556 · start 2022-07-07

    Registered record
    Registry ID
    NCT05444556
    Conditions
    Healthy
    Interventions
    Imlunestrant; Repaglinide; Omeprazole; Dextromethorphan; Quinidine; Rosuvastatin; Digoxin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-07-07
    Completion
    2022-11-02
    Enrolment
    113

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionImlunestrant; Repaglinide; Omeprazole; Dextromethorphan +3 more
    PhasePhase 1
    Registry statusCompleted

  • Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Food Effect and DDI of Ascending Doses of the MEK Inhibitor Zapnometinib

    NCT05555823 · start 2022-06-23

    Registered record
    Registry ID
    NCT05555823
    Conditions
    Healthy
    Interventions
    ATR-002; Placebo; Repaglinide; Celecoxib
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-06-23
    Completion
    2023-07-20
    Enrolment
    96

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionATR-002; Placebo; Repaglinide; Celecoxib
    PhasePhase 1
    Registry statusCompleted

  • Drug-drug Interaction Study of Ganaplacide and Lumefantrine With Midazolam, Repaglinide, Dextromethorphan, Metformin, Rosuvastatin and Dolutegravir

    NCT05236530 · start 2022-03-09

    Registered record
    Registry ID
    NCT05236530
    Conditions
    Malaria
    Interventions
    Midazolam; Repaglinide; Dextromethorphan; Metformin; Ganaplacide; Lumefantrine; Rosuvastatin; Dolutegravir; Ganaplacide; Lumefantrine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2022-03-09
    Completion
    2022-10-17
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMalaria
    InterventionMidazolam; Repaglinide; Dextromethorphan; Metformin +6 more
    PhasePhase 1
    Registry statusCompleted